The PREVENT‐AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond

The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community, as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection. HIGHLIGHTS: The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is a single-site longitudinal study that started in 2011 with annual follow-up data collection on individuals at risk of Alzheimer's disease who were all cognitively normal at enrolment. All 387 participants were enrolled between 2011 and 2017 and 306 (79%) of these participants were still in the study as of December 2023. While the PREVENT-AD dataset was not originally planned to be shared with the global research community, 348 participants retrospectively consented for their data to be shared with researchers worldwide. The first release of data was in 2019. We now share a second release that includes 6 years of additional follow-up visits, information on clinical progression and novel cognitive, behavioral, genetic, plasma and neuroimaging (amyloid and tau positron emission tomography [PET], magnetoencephalography [MEG], and new magnetic resonance imaging [MRI] sequences) data. It also includes analytic outputs for neuroimaging modalities.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-09-29
DOI
https://doi.org/10.1002/alz.70653
Citations
3
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
4.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The PREVENT‐AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond

Andrée‐Ann Baril, Christian Bocti, Jennifer Tremblay‐Mercier, Pierre Bellec et al.
3 citations
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
4.41
article

The PREVENT‐AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond

Andrée‐Ann Baril, Christian Bocti, Jennifer Tremblay‐Mercier, Pierre Bellec, Alan C. Evans, Étienne Vachon‐Presseau, Alexa Pichet Binette, Mohammadali Javanray, Judes Poirier, M. Mallar Chakravarty, Béry Mohammediyan, Jordana Remz, Kaj Blennow, Maiya R. Geddes, Cherie Strikwerda‐Brown, Christos A. Davatzikos, Jean‐Paul Soucy, Christine Tardif, Sylvain Baillet, Maxime Descoteaux, Manon Edde, Mahsa Dadar, Alexandre Pastor‐Bernier, John C.S. Breitner, Valentin Ourry, Natasha Rajah, Alfie Wearn, D. Louis Collins, Yara Yakoub, Maxime Montembeault, Safa Sanami, R. Nathan Spreng, Sylvia Villeneuve, Julie Gonneaud, Robert Laforce, Claudine Joëlle Gauthier, Pedro Rosa‐Neto, Ting Qiu, Jonathan Gallego‐Rudolf, Amelie Metz, Simon Ducharme, Jean‐Michel Raoult, Henrik Zetterberg, Alfonso Fajardo Valdez
article en
3 citations

Abstract

The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community, as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection. HIGHLIGHTS: The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is a single-site longitudinal study that started in 2011 with annual follow-up data collection on individuals at risk of Alzheimer's disease who were all cognitively normal at enrolment. All 387 participants were enrolled between 2011 and 2017 and 306 (79%) of these participants were still in the study as of December 2023. While the PREVENT-AD dataset was not originally planned to be shared with the global research community, 348 participants retrospectively consented for their data to be shared with researchers worldwide. The first release of data was in 2019. We now share a second release that includes 6 years of additional follow-up visits, information on clinical progression and novel cognitive, behavioral, genetic, plasma and neuroimaging (amyloid and tau positron emission tomography [PET], magnetoencephalography [MEG], and new magnetic resonance imaging [MRI] sequences) data. It also includes analytic outputs for neuroimaging modalities.

Alzheimer s & DementiaVol. 21(10)
University of Science and Technology of China (CN), Montreal Neurological Institute and Hospital (CA), Université de Sherbrooke (CA), Inserm (FR), The University of Western Australia (AU), Lund University (SE), Douglas Mental Health University Institute (CA), Montreal Heart Institute (CA), Sahlgrenska University Hospital (SE), McGill University Health Centre (CA), Sorbonne Université (FR), Normandie Université (FR), Institute for Neurodegenerative Disorders (US), Pitié-Salpêtrière Hospital (FR), UK Dementia Research Institute (GB), Institut Universitaire de Gériatrie de Montréal (CA), Resources for Human Development (US), Hôpital du Sacré-Cœur de Montréal (CA), Institut du Cerveau (FR), Cyceron (FR), Université Laval (CA), University College London (GB), McGill University (CA), Toronto Metropolitan University (CA), Concordia University (CA), Université de Montréal (CA), University of Gothenburg (SE), Université de Caen Normandie (FR)
Openalex Percentile: Top 5%
Dementia and Cognitive Impairment Research
4.41
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.